BROLUCIZUMAB

Other

Brand names: BEOVU

Intravitreal

Mechanism of Action

12.1 Mechanism of Action Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110 , VEGF 121 , and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.

Indications

See full prescribing information

Contraindications

• pruritus
• urticaria
• erythema
• or severe intraocular inflammation.

FDA Warnings

5 WARNINGS AND PRECAUTIONS Endophthalmitis and retinal detachment may occur following intravitreal injections
There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors ( 5
Patients treated with BEOVU who experience intraocular inflammation may be at risk of developing retinal vasculitis and/or retinal vascular occlusion and should be closely monitored [see Contraindications (4
4 Thromboembolic Events Although there was a low rate of arterial thromboembolic events (ATEs) observed in the BEOVU clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors

Known Side Effects

2 documented side effects by frequency

Blurred Vision

1-10%

Drug Not Working

0.1-1%

Community Discussions

No community discussions found for BROLUCIZUMAB yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravitreal